New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:24 EDTITMNInterMune upgraded to Outperform from Market Perform at Leerink
Leerink upgraded InterMune to Outperform saying data at the American Thoracic Society presents a strong case that favors the use Esbriet over Boehringer-Ingelheim's nintedanib in idiopathic pulmonary fibrosis. The firm keeps a $41 price target for shares.
News For ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ITMN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use